Trials / Recruiting
RecruitingNCT06730750
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986490 | Specified dose on specified days. |
| DRUG | Bevacizumab | Specified dose on specified days. |
Timeline
- Start date
- 2025-02-12
- Primary completion
- 2026-09-05
- Completion
- 2029-12-09
- First posted
- 2024-12-12
- Last updated
- 2025-12-15
Locations
6 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06730750. Inclusion in this directory is not an endorsement.